• SnoreStop® Starter Kit
  • SnoreStop® Starter Kit
  • SnoreStop® Starter Kit
  • SnoreStop® Starter Kit

SnoreStop® Starter Kit

Nasal Spray, Tablets & Throat Spray - RISK-FREE TRIAL - Online Exclusive!

SKU: 001

About The Product



Snoring is a noisy wedge that pries people apart. Night after night your snoring is a sign that not only your breathing is disturbed but also your sleep. You are in fact not resting as you should, you are struggling to breathe. The end result is you are not starting a new day charged up but unplugged. 

We offer a device free solution. As easy as 1, 2, 3. 

The Starter Kit includes three trial size products. Each one targets a separate location where snoring can occur.
A nasal spray for the nose, a tablet for the mouth, and a throat spray for the back of the throat.
The kit will help you determine where your snoring occurs and which SnoreStop product works best for you. Sleep soundly without having to wear a cumbersome device. 
For best results, we recommend repeated use of each product for 3 to 5 consecutive nights. Eat, drink, and/or take any medicine at least 30 minutes prior to taking SnoreStop at bedtime.


* Individual results may vary.



 Click each product below for list of ingredients:

SnoreStop NasoSpray (nasal spray)

SnoreStop FastTabs (tablets)

SnoreStop Extinguisher (throat spray) 

SnoreStop formulas are prepared in accordance with the Homeopathic Pharmacopoeia of the United States (HPUS). All ingredients are recognized as an official collection of accepted drug ingredients by the Federal Food, Drug and Cosmetic Act and are manufactured in FDA-approved laboratories. Each natural ingredient comes either from plant, mineral or protein sources and is present only in harmless microscopic amounts in each dose. None of our ingredients contain any alkaloids, ephedrine or pseudo - ephedrine. SnoreStop is a natural homeopathic over-the-counter medicine regulated by the FDA.

Dilution Scale: 6X is equal to one part per million.

Claims follow requirement in CPG 400.400 and GLP of Sections 502 & 503 of the FDCA (“The Act”) and Part 201 Title 21 of the CFR to include Principle Display Panel of OTC Drug Labeling under 21 CFR 201.62. Uses and claims are taken from various authorized Materia Medica for references. They have not been reviewed by the Federal Drug and Administration.